RGNX logo

REGENXBIO (RGNX)

Profile

Full Name

REGENXBIO Inc.

Ticker Symbol

RGNX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 17, 2015

Indexes

Not included

Website

http://www.regenxbio.com

Employees

353

Key Details

Price

$5.89(+8.87%)

Market cap

$295.01M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$83.33M(-7.66% YoY)

Annual EPS

-$4.59(+23.75% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$5.89
RGNX price is $5.89

30-Day Relative Volume

1.13
RGNX 30-day relative volume is 1.13

Price Performance

Price Today change

+8.87%
RGNX price is up +8.87% today

Price YTD change

-23.8%
RGNX price is down -23.8% since January 1st

Price 1-year change

-69.03%
RGNX price is down -69.03% year-on-year

Price 3-year change

-80.7%
RGNX price is down -80.7% over the past 3 years

Price Range

Price All-time high

$85.10
RGNX price is currently -93.08% below its historical high of $85.10

Price 3-year low

$5.04
RGNX price is currently +16.98% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$295.01M
RGNX market capitalization is $295.01 million

Market cap 3-year change

-77.51%
RGNX market capitalization is down -77.51% over the past 3 years

Market cap All-time high

$2.88B
RGNX market capitalization is currently -89.74% below its historical high of $2.88 billion

Market cap sector rank

62.86%
RGNX market capitalization is higher than 62.86% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+2.13%
RGNX shares outstanding is up +2.13% year-on-year

Shares Outstanding 3-Year Change

+16.52%
RGNX shares outstanding is up +16.52% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.40
RGNX beta is 1.40

200-day SMA

$9.59
RGNX price is currently -38.56% below its 200-day simple moving average

50-day SMA

$7.11
RGNX price is currently -17.19% below its 50-day simple moving average

RSI

40.87
RGNX 14-day relative strength index is 40.87

Volume

1.13
RGNX 30-day relative volume is 1.13

ATR

$0.62
RGNX average true range is $0.62

10-day Historical Volatility

123.03%
RGNX 10-day historical volatility is 123.03%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$83.33M
RGNX annual revenue is $83.33 million

Revenue Analysts estimate

$325.28M
RGNX annual revenue is currently -74.38% lower than the consensus analysts' forecast

Revenue 1-year change

-7.66%
RGNX annual revenue is down -7.66% year-on-year

Revenue Sector rank

54.2%
RGNX annual revenue is higher than 54.2% of companies in Healthcare sector

EPS

EPS

-$4.59
RGNX annual earnings per share is -$4.59

EPS Analysts estimate

-$0.98
RGNX annual earnings per share is currently +367.37% higher than the consensus analysts' forecast

EPS 1-year change

+23.75%
RGNX annual earnings per share is up +23.75% year-on-year

EPS Sector rank

20.4%
RGNX annual earnings per share is higher than 20.4% of companies in Healthcare sector

Profit

Gross profit

$49.76M
RGNX annual gross profit is $49.76 million

Gross margin

59.72%
RGNX annual gross profit margin is 59.72%

Operating profit

-$231.25M
RGNX annual operating income is -$231.25 million

Operating margin

-277.51%
RGNX annual operating profit margin is -277.51%

Net income

-$227.10M
RGNX annual net profit is -$227.10 million

Net margin

-272.54%
RGNX annual net profit margin is -272.54%

Expenses

Total expenses

$314.57M
RGNX annual total expenses is $314.57 million

Operating expenses

$281.01M
RGNX annual total operating expenses is $281.01 million

Cost of goods sold

$33.57M
RGNX annual cost of goods sold is $33.57 million

Selling, general & administrative expenses

$76.62M
RGNX annual SGA is $76.62 million

Depreciation and amortization

$16.21M
RGNX annual depreciation & amortization is $16.21 million

Interest expense

$12.66M
RGNX annual interest expense is $12.66 million

Income tax

$0.00
RGNX annual income tax is $0.00

EBIT & EBITDA

EBIT

-$214.44M
RGNX annual earnings before interest & taxes is -$214.44 million

EBITDA

-$198.23M
RGNX annual EBITDA is -$198.23 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$465.99M
RGNX annual total assets is $465.99 million

Non current assets

$187.99M
RGNX annual long term assets is $187.99 million

Current assets

$278.00M
RGNX annual total current assets is $278.00 million

Cash and cash equivalents

$57.53M
RGNX annual cash & cash equivalents is $57.53 million

Accounts receivable

$65.00K
RGNX annual accounts receivable is $65.00 thousand

Inventory

-
RGNX annual inventory value is unknown

Liabilities

Total liabilities

$206.34M
RGNX annual total liabilities is $206.34 million

Long term liabilities

$103.14M
RGNX annual total long term liabilities is $103.14 million

Current liabilities

$103.19M
RGNX annual total current liabilities is $103.19 million

Accounts payable

$22.80M
RGNX annual accounts payable is $22.80 million

Debt

Total debt

$82.03M
RGNX annual total debt is $82.03 million

Total debt 1-year change

-8.13%
RGNX annual total debt is down -8.13% year-on-year

Long term debt

$74.13M
RGNX annual long term debt is $74.13 million

Short term debt

$7.90M
RGNX annual short term debt is $7.90 million

Equity & Capital

Shareholders equity

$259.65M
RGNX annual stockholders equity is $259.65 million

Book value

$259.65M
RGNX annual book value is $259.65 million

Retained earnings

-$932.15M
RGNX annual retained earnings is -$932.15 million

Working capital

$174.81M
RGNX annual working capital is $174.81 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$173.13M
RGNX annual cash flow from operations is -$173.13 million

Cash from operations 1-year change

+20.73%
RGNX annual cash flow from operations is up +20.73% year-on-year

Cash from investing

$103.45M
RGNX annual cash flow from investing activities is $103.45 million

Cash from investing 1-year change

-45.82%
RGNX annual cash flow from investing activities is down -45.82% year-on-year

Cash from financing

$92.68M
RGNX annual cash flow from financing activities is $92.68 million

Cash from financing 1-year change

+365.07%
RGNX annual cash flow from financing activities is up +365.07% year-on-year

CAPEX

CAPEX

$2.44M
RGNX annual capital expenditures is $2.44 million

CAPEX 1-year change

-75.54%
RGNX annual capital expenditures is down -75.54% year-on-year

Free Cash Flow

Free cash flow

-$175.56M
RGNX annual free cash flow is -$175.56 million

Free cash flow 1-year change

+23.12%
RGNX annual free cash flow is up +23.12% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

59.72%
RGNX annual gross profit margin is 59.72%

Operating margin

-277.51%
RGNX annual operating profit margin is -277.51%

Net margin

-272.54%
RGNX annual net profit margin is -272.54%

ROA & ROE

ROA

-43.68%
RGNX annual return on assets is -43.68%

ROE

-79.49%
RGNX annual return on equity is -79.49%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RGNX price to earnings ratio value is unknown

PE ratio Sector rank

-
RGNX price to earnings ratio is unknown

PB Ratio

PB ratio

1.14
RGNX price to book ratio is 1.14

PB ratio Sector rank

47.45%
RGNX price to book ratio is higher than 47.45% of companies in Healthcare sector

PS Ratio

PS ratio

3.54
RGNX price to sales ratio is 3.54

PS ratio Sector rank

58.21%
RGNX price to sales ratio is higher than 58.21% of companies in Healthcare sector

Enterprise value

Enterprise value

$319.51M
RGNX enterprise value is $319.51 million

Enterprise value Sector rank

64.14%
RGNX enterprise value is higher than 64.14% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.61
RGNX EV/EBITDA is -1.61

EV/EBITDA Sector rank

35.42%
RGNX EV/EBITDA is higher than 35.42% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.69
RGNX annual current ratio is 2.69

Quick ratio

-
RGNX annual quick ratio value is unknown

Leverage

Debt to equity

0.00
RGNX annual debt to equity ratio is 0.00

Interest coverage ratio

-16.94
RGNX annual interest coverage ratio is -16.94

Risk & Stability

Piotroski F-Score

5
RGNX piotroski f-score is 5

Altman Z-Score

-2.83
RGNX altman z-score is -2.83

Analyst ratings

Recent major analysts updates

Mar 21, 25 HC Wainwright & Co.
Buy
Mar 20, 25 HC Wainwright & Co.
Buy
Mar 20, 25 Chardan Capital
Buy
Mar 17, 25 HC Wainwright & Co.
Buy
Mar 14, 25 Morgan Stanley
Overweight
Mar 14, 25 Chardan Capital
Buy
Feb 11, 25 Goldman Sachs
Neutral
Jan 21, 25 RBC Capital
Outperform
Jan 15, 25 HC Wainwright & Co.
Buy
Dec 11, 24 RBC Capital
Outperform

Institutional Ownership

Similar stocks

VERV logo
Verve Therapeutics (VERV)
HCAT logo
Health Catalyst (HCAT)
RNAC logo
Cartesian Therapeutics (RNAC)
Anbio Biotechnology Class A (NNNN)
PSNL logo
Personalis (PSNL)
Oruka Therapeutics (ORKA)
HRTX logo
Heron Therapeutics (HRTX)
NNOX logo
Nano-X Imaging (NNOX)
BNTC logo
Benitec Biopharma (BNTC)
  • What is the ticker symbol for REGENXBIO?
  • Does REGENXBIO pay dividends?
  • What sector is REGENXBIO in?
  • What industry is REGENXBIO in?
  • What country is REGENXBIO based in?
  • When did REGENXBIO go public?
  • Is REGENXBIO in the S&P 500?
  • Is REGENXBIO in the NASDAQ 100?
  • Is REGENXBIO in the Dow Jones?
  • When was REGENXBIO's last earnings report?
  • When does REGENXBIO report earnings?
  • Should I buy REGENXBIO stock now?

What is the ticker symbol for REGENXBIO?

The ticker symbol for REGENXBIO is NASDAQ:RGNX

Does REGENXBIO pay dividends?

No, REGENXBIO does not pay dividends

What sector is REGENXBIO in?

REGENXBIO is in the Healthcare sector

What industry is REGENXBIO in?

REGENXBIO is in the Biotechnology industry

What country is REGENXBIO based in?

REGENXBIO is headquartered in United States

When did REGENXBIO go public?

REGENXBIO's initial public offering (IPO) was on September 17, 2015

Is REGENXBIO in the S&P 500?

No, REGENXBIO is not included in the S&P 500 index

Is REGENXBIO in the NASDAQ 100?

No, REGENXBIO is not included in the NASDAQ 100 index

Is REGENXBIO in the Dow Jones?

No, REGENXBIO is not included in the Dow Jones index

When was REGENXBIO's last earnings report?

REGENXBIO's most recent earnings report was on Mar 13, 2025

When does REGENXBIO report earnings?

The next expected earnings date for REGENXBIO is May 8, 2025

Should I buy REGENXBIO stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page